The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1429
An OTC Corticosteroid Nasal Spray for Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ. The OTC product, which is scheduled to be marketed in the spring of 2014, will be the first corticosteroid nasal spray that can be purchased without a prescription in the US. Nasacort Allergy 24HR is approved for use in patients ≥2 years old with nasal allergy symptoms.

CLINICAL USE — Intranasal corticosteroids are more effective than intranasal antihistamines for prevention and relief of allergic rhinitis symptoms, including itching, sneezing, discharge, and congestion, and are the drugs of choice for moderate-to-severe disease.1 Most of these agents are effective when given once or twice daily. The onset of action typically occurs within 12 hours, but maximal effects may not ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: An OTC Corticosteroid Nasal Spray for Allergic Rhinitis
Article code: 1429c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian